HER2低蛋白表达的管腔型与三阴性乳腺癌特征分析
研究纳入Nottingham队列(n=5744)和TCGA乳腺癌队列(n=854),分析HER2低表达乳腺癌的临床病理、分子及免疫特征。结果显示90%的HER2低表达肿瘤为激素受体阳性,富集管腔型分子亚型,与HER2阴性乳腺癌相比临床行为无显著差异;在激素受体阴性乳腺癌中,HER2低表达肿瘤侵袭性较低、患者生存期较长,且多富集管腔雄激素受体亚型及独特免疫特征。
要点
- 90%的HER2低表达肿瘤为激素受体阳性,富集管腔型分子亚型。
- 激素受体阳性乳腺癌中,HER2低表达与HER2阴性肿瘤无显著预后差异。
- 激素受体阴性乳腺癌中,HER2低表达肿瘤侵袭性较低、生存期较长,多富集管腔雄激素受体亚型。
核心结论
- HER2低表达乳腺癌在激素受体阳性肿瘤中主要由激素受体信号驱动。
- 激素受体阴性/HER2低表达肿瘤倾向于富集管腔雄激素受体基因,具有独特免疫特征。
研究设计与样本
- 研究纳入两个独立且特征明确的乳腺癌队列:Nottingham队列(A,n=5744)和癌症基因组图谱(TCGA)乳腺癌队列(B,n=854)。
- 研究分析HER2低表达乳腺癌的临床、分子、生物学及免疫特征。
- 在TCGA乳腺癌队列中进行转录组和通路富集分析,并在部分Nottingham病例中通过下一代测序验证。
主要发现
- 90%的HER2低表达肿瘤为激素受体阳性,富集管腔型内在分子亚型,缺乏HER2致癌信号基因的显著表达,与HER2阴性乳腺癌相比无显著有利临床行为。
- 在激素受体阳性乳腺癌中,HER2低表达与HER2阴性肿瘤之间未检测到显著预后差异。
- 在激素受体阴性乳腺癌中,HER2低表达肿瘤侵袭性较低,患者生存期较长。
- 转录组数据显示,大多数激素受体阴性/HER2低表达肿瘤为管腔雄激素受体内在亚型,富集辅助性T淋巴细胞、活化树突状细胞和肿瘤相关中性粒细胞;而大多数激素受体阴性/HER2阴性肿瘤为基底样型,富集肿瘤相关巨噬细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of HER2 Low BC including response to therapy and patient outcome in the adjuvant and neoadjuvant settings. METHODS: Two different independent and well-characterised BC cohorts were included. Nottingham cohort (A) (n = 5744) and The Cancer Genome Atlas (TCGA) BC cohort (B) (n = 854). The clinical, molecular, biological and immunological profile of HER2 Low BC was investigated. Transcriptomic and pathway enrichment analyses were performed on the TCGA BC cohort and validated through next-generation sequencing in a subset of Nottingham cases. RESULTS: Ninety percent of HER2 Low tumours were hormone receptor (HR) positive (HR+), enriched with luminal intrinsic molecular subtype, lacking significant expression of HER2 oncogenic signalling genes and of favourable clinical behaviour compared to HER2 negative (HER2-) BC. In HR+ BC, no significant prognostic differences were detected between HER2 Low and HER2- tumours. However, in HR- BC, HER2 Low tumours were less aggressive with longer patient survival. Transcriptomic data showed that the majority of HR- /HER2 Low tumours were of luminal androgen receptor (LAR) intrinsic subtype, enriched with T-helper lymphocytes, activated dendritic cells and tumour associated neutrophils, while most HR-/HER2- tumours were basal-like, enriched with tumour associated macrophages. CONCLUSION: HER2 Low BC is mainly driven by HR signalling in HR+ tumours. HR-/HER2 Low tumours tend to be enriched with LAR genes with a unique immune profile.
引用
- Atallah NM, Haque M, Quinn C, et al. Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. Eur J Cancer. 2023. PMID: 37897865. doi:10.1016/j.ejca.2023.113371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。